HIF1A and neoplasm: Additionally, inhibiting HIF-1α with echinomycin decreases PD-L1 expression on tumor cells, TAMs, and MDSCs when combined with anti-CTLA4 ICI therapy (33).Importantly, echinomycin augmented PD-L1 expression in normal tissues, promoting tolerance and protecting against immune-related adverse effects of ICIs (33).